时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
In a second step, we reviewed the abstracts of data articles identified during the first search to determine whether details about clinical trials were provided.；Altogether, this combination of less-than-optimal conditions could explain why AL002 failed to meet its clinical objectives.；Enrollment was completed, and the investigators are analyzing the data, hence the results are unavailable.Whether targeting Tregs via IL-2 supplementation is an efficient approach to improve clinical outcomes in AD patients is unclear to date.
方法
This is an increasingly concerning situation for governments and health organizations, as the current estimated lifetime cost of care exceeds $400,000 per dementia patient in high-income countries.1 With the number of AD cases estimated to double by 2060, the healthcare, economic, and familial burden of caring for ADRD patients is putting social benefit programs under extreme pressure.；This conceptual framework could partly explain why targeting Aβ alone might not be sufficient to stop the progression of AD,14 ie, both tau and neuroinflammation are still ongoing in the brain of patients affected by AD/ADRD, thereby potentially hindering anti-amyloid therapies.；In this context, our group has been investigating such an approach since the late 2000s, where we repurposed the tumor necrosis factor alpha (TNF-α), an anti-cancer drug, thalidomide, in AD patients.
核心结论
Several preclinical studies have been conducted in rodents to validate TREM2 activation as a therapeutic strategy and are summarized in a very recent review that we recommend to those interested in this topic.52 In summary, AL002 reduced brain amyloid loads and increased the number of microglial cells in AD mouse models.；However, the data showed that AL002 was relatively well tolerated in this cohort, besides some ARIA events, and engaged its target, as demonstrated by decreases from baseline to end of dosing in CSF sTREM2 across all dose groups versus placebo, though no dose‑response pattern was noted.54 Given these negative results, the sponsors decided that AL002 will not proceed to Phase 3 for the treatment of AD.The failure of this agent to improve AD clinical outcomes may stem from several issues.；These results prompted the conduction of a Phase 2a, randomized, double-blind, placebo-controlled clinical trial (NCT06096090) testing placebo or low-dose subcutaneous IL-2 (106 IU/day) for five days, administered either every 2 or 4 weeks, for 21 weeks, followed by 9 weeks of observation, in 38 AD subjects (age range 50–86 years old; MMSE score ranging 12–26).
局限
Such a review should help the reader understand the numerous approaches engineered to modulate central inflammation, as well as the similarities and differences in clinical‑trial designs that could, at least in part, explain the failure of some of these trials.Material and MethodsFor this narrative review, we searched several databases with a date limitation of 2001–2026.；However, foralumab treatment increased the number of Tregs in the periphery and promoted the infiltration of T cells into the brain, where they co-localized with microglia.；However, the data showed that AL002 was relatively well tolerated in this cohort, besides some ARIA events, and engaged its target, as demonstrated by decreases from baseline to end of dosing in CSF sTREM2 across all dose groups versus placebo, though no dose‑response pattern was noted.54 Given these negative results, the sponsors decided that AL002 will not proceed to Phase 3 for the treatment of AD.The failure of this agent to improve AD clinical outcomes may stem from several issues.
对本项目的价值
中高价值：属「衰老细胞清除 / SASP 轴」方向；细胞衰老 / senolytics / SASP栏目可用作本项目文献库与综述素材。 ｜ 价值分 3.1/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 94,398 字符，题名指纹 0.89，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：阿尔茨海默病新兴与再定位的免疫调节剂
- 英文标题：Emerging and Repurposed Immune System Modulators for Alzheimer's Disease.
- 期刊与标识：Drug design, development and therapy · PMID 42979167 · DOI 10.2147/DDDT.S559284 · PMC PMC13729761